Mirae Asset Global Investments
NBIX icon

Mirae Asset Global Investments’s Neurocrine Biosciences NBIX Stock Holding History

Mirae Asset Global Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.63M Sell
9,700
-708
-7% -$105K ﹤0.01% 813
2026
Q1 		$1.37M Sell
10,408
-6,308
-38% -$837K ﹤0.01% 805
2025
Q4 		$2.37M Buy
16,716
+1,995
+14% +$289K 0.01% 748
2025
Q3 		$2.07M Buy
14,721
+2,208
+18% +$299K 0.01% 742
2025
Q2 		$1.57M Sell
12,513
-1,064
-8% -$122K 0.01% 752
2025
Q1 		$1.52M Sell
13,577
-2,781
-17% -$352K 0.01% 744
2024
Q4 		$2.25M Buy
16,358
+2,925
+22% +$362K 0.01% 628
2024
Q3 		$1.55M Buy
13,433
+9,601
+251% +$1.32M 0.01% 710
2024
Q2 		$515K Sell
3,832
-9,468
-71% -$1.3M ﹤0.01% 918
2024
Q1 		$1.52M Sell
13,300
-13,688
-51% -$1.87M ﹤0.01% 1336
2023
Q4 		$3.56M Sell
26,988
-2,074
-7% -$239K 0.01% 1020
2023
Q3 		$3.3M Sell
29,062
-6,502
-18% -$685K 0.01% 986
2023
Q2 		$3.36M Sell
35,564
-3,729
-9% -$364K 0.01% 1008
2023
Q1 		$3.94M Buy
39,293
+12,663
+48% +$1.32M 0.01% 934
2022
Q4 		$3.19M Sell
26,630
-5,889
-18% -$690K 0.01% 953
2022
Q3 		$3.39M Sell
32,519
-4,613
-12% -$468K 0.01% 938
2022
Q2 		$3.62M Sell
37,132
-1,310
-3% -$121K 0.01% 938
2022
Q1 		$3.6M Sell
38,442
-5,064
-12% -$429K 0.01% 973
2021
Q4 		$3.69M Sell
43,506
-2,681
-6% -$247K 0.01% 967
2021
Q3 		$4.43M Buy
46,187
+5,642
+14% +$533K 0.01% 877
2021
Q2 		$3.94M Sell
40,545
-1,105
-3% -$106K 0.01% 871
2021
Q1 		$4.05M Sell
41,650
-9,705
-19% -$1.02M 0.01% 777
2020
Q4 		$4.92M Buy
51,355
+11,726
+30% +$1.13M 0.02% 656
2020
Q3 		$3.83M Buy
39,629
+1,186
+3% +$137K 0.02% 605
2020
Q2 		$4.69M Sell
38,443
-7,806
-17% -$863K 0.03% 519
2020
Q1 		$4M Sell
46,249
-193,081
-81% -$18.9M 0.03% 484
2019
Q4 		$25.7M Sell
239,330
-6,554
-3% -$686K 0.16% 148
2019
Q3 		$22.2M Sell
245,884
-56,650
-19% -$5.29M 0.15% 161
2019
Q2 		$25.5M Sell
302,534
-3,799
-1% -$312K 0.17% 129
2019
Q1 		$27M Buy
306,333
+40,572
+15% +$3.39M 0.2% 114
2018
Q4 		$19M Buy
265,761
+15,861
+6% +$1.52M 0.17% 133
2018
Q3 		$30.7M Buy
249,900
+164,306
+192% +$18.6M 0.23% 101
2018
Q2 		$8.41M Buy
85,594
+5,302
+7% +$475K 0.11% 122
2018
Q1 		$6.66M Buy
80,292
+26,930
+50% +$2.27M 0.09% 148
2017
Q4 		$4.14M Buy
53,362
+37,690
+240% +$2.57M 0.06% 215
2017
Q3 		$961K Buy
+15,672
New +$827K 0.02% 431

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Mirae Asset Global Investments's NBIX Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Neurocrine Biosciences (NBIX) stake by 6.8% in Q2 2026, selling an estimated $105K and leaving 9,700 shares worth $1.63M. The position accounts for ﹤0.01% of the portfolio, ranked #813.

Mirae Asset Global Investments first reported a position in NBIX in Q3 2017 and has held it in 36 quarters since. The position peaked at $30.7M in Q3 2018. 405 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Mirae Asset Global Investments held 9,700 shares of Neurocrine Biosciences worth $1.63M as of Q2 2026.
  • Mirae Asset Global Investments sold 708 Neurocrine Biosciences shares in Q2 2026, an estimated $105K.
  • Neurocrine Biosciences made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #813 holding.
  • Mirae Asset Global Investments first reported a position in Neurocrine Biosciences in Q3 2017 and has held it in 36 quarters since.
  • Mirae Asset Global Investments's Neurocrine Biosciences position peaked at $30.7M in Q3 2018.
  • 405 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.